You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PARP-I

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HRD Cancer, SCLC, Advanced Solid Tumors Trial run by the NCI (Berzosertib, Sacituzumab Govitecan)

Recruiting
  • HRD Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))

Active, not recruiting
  • Ovarian Neoplasms
  • +2 more
  • KU-0059436 (AZD2281)(PARP inhibitor)
  • Brussels, Belgium
  • +4 more
Dec 19, 2022

Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin Trial in Belgium, Netherlands, United Kingdom

Active, not recruiting
  • Triple Negative Metastatic Breast Cancer
  • +3 more
  • KU-0059436 (AZD2281)(PARP inhibitor)
  • +3 more
  • Brussels, Belgium
  • +3 more
Dec 19, 2022

Metastatic Cancer, Unspecified Adult Solid Tumor Trial in Los Angeles (PARP inhibitor BMN-673, temozolomide, irinotecan HCl)

Completed
  • Metastatic Cancer
  • Unspecified Adult Solid Tumor
  • PARP inhibitor BMN-673
  • +4 more
  • Los Angeles, California
    Jonsson Comprehensive Cancer Center
Sep 22, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial (procedure, biological,

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +5 more
  • (no location specified)
Apr 8, 2023

Acute Myeloid Leukemia Trial in Stanford (Talazoparib, Topotecan, Gemcitabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Stanford, California
    Stanford University
Jun 10, 2022

Breast Tumors Trial in Guangzhou (procedure, drug, biological)

Recruiting
  • Breast Neoplasms
  • Surgery for harvesting tumor-draining lymph nodes
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Nov 2, 2023

Prostate Cancer Trial in United States (Niraparib, Leuprolide, Abiraterone Acetate)

Recruiting
  • Prostate Cancer
  • Ann Arbor, Michigan
  • +3 more
Oct 18, 2022

Solid Tumor, Extensive-stage Small-cell Lung Cancer, Locally Advanced Breast Cancer Trial in Czechia, Poland (RP12146)

Recruiting
  • Solid Tumor
  • +6 more
  • Hořovice, Czechia
  • +5 more
Jun 8, 2022

Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston (drug,

Recruiting
  • Extensive Stage Lung Small Cell Carcinoma
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 8, 2022

Tumors Trial in Bethesda, Boston, Houston (Veliparib + VX-970 + Cisplatin)

Completed
Has Results
  • Neoplasms
  • Veliparib + VX-970 + Cisplatin
  • Bethesda, Maryland
  • +2 more
Jan 14, 2022

Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal

Recruiting
  • Borderline Resectable Pancreatic Adenocarcinoma
  • +11 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Mar 22, 2022

Endometrial Serous Adenocarcinoma, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in United States

Recruiting
  • Endometrial Serous Adenocarcinoma
  • +2 more
  • Biopsy
  • +3 more
  • Phoenix, Arizona
  • +3 more
Feb 2, 2023

Advanced Solid Tumors Trial in Seongnam-si, Seoul (JPI-547)

Completed
  • Advanced Solid Tumors
  • Seongnam-si, Gyeonggi-do, Korea, Republic of
  • +1 more
Jun 1, 2022

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Active, not recruiting
  • Acute Lymphoblastic Leukemia
  • +15 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Chicago, Illinois
  • +2 more
Jan 12, 2023

Malignant Solid Tumor Trial in United States (drug, other, procedure)

Active, not recruiting
  • Malignant Solid Neoplasm
  • Baltimore, Maryland
  • +5 more
Nov 8, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

Active, not recruiting
Has Results
  • BRCA1 Gene Mutation
  • +5 more
  • Durvalumab
  • +3 more
  • Buffalo, New York
  • +1 more
Jan 20, 2023

Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Solid Tumor Trial in New Brunswick

Active, not recruiting
  • Ann Arbor Stage III Non-Hodgkin Lymphoma
  • +2 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Jan 28, 2023

Ewing Sarcoma Trial in United Kingdom, United States (niraparib, Temozolomide, Irinotecan)

Completed
  • Ewing Sarcoma
  • Los Angeles, California
  • +4 more
Jan 8, 2021

Ovarian Cancer, Breast Cancer Trial in Boston, New York, Houston (BKM120 and Olaparib, BYL719 and Olaparib)

Completed
  • Ovarian Cancer
  • Breast Cancer
  • BKM120 and Olaparib
  • BYL719 and Olaparib
  • Boston, Massachusetts
  • +4 more
Feb 8, 2021

Small Cell Lung Cancer SCLC Trial in München Gauting (veliparib, Topotecan)

Recruiting
  • Small Cell Lung Cancer SCLC
  • München Gauting, Germany
    Klinik München Gauting
Jan 26, 2021

Breast Tumors, Triple-Negative, Breast Tumor Malignant Female, Radiotherapy Side Effect Trial in Paris (Olaparib, Radiation

Active, not recruiting
  • Breast Neoplasms, Triple-Negative
  • +2 more
  • Paris, France
    Institut Curie
Oct 23, 2020

Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy Trial in Rotterdam (olaparib)

Recruiting
  • Neuroendocrine Tumors
  • Peptide Receptor Radionuclide Therapy
  • Rotterdam, South Holland, Netherlands
    Erasmus MC
May 19, 2023

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma

Not yet recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +3 more
  • (no location specified)
Jul 28, 2023

Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC

Terminated
Has Results
  • Prostate Adenocarcinoma Without Neuroendocrine Differentiation
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 1, 2020